China's National Medicines Control Administration (NMPA) has announced that the marketing application for lisdexamfetamine transdermal patch (twice a week) has been approved. According to the press release, this is a twice-weekly, transdermal delivery of lisdexamfetamine modified patch (R&D code LY03013), which is approved for the treatment of symptoms of mild to moderate Alzheimer's disease.LY03013, through the route of administration innovation, was developed in-house on the transdermal release technology platform of Luye Pharma, a German subsidiary of Greenleaf Pharmaceuticals, and is already marketed and licensed in several European countries.
Alzheimer's disease is an irreversible neurodegenerative disease that causes progressive decline in memory and other cognitive aspects of patients. Publicly available data show that dementia associated with Alzheimer's disease is the most common type of dementia, accounting for 60% to 80% of all dementia patients.
Lisdexamfetamine is a drug in the cholinesterase inhibitor class that is used clinically to treat mild to moderate dementia associated with Alzheimer's disease. This class of drugs improves cognitive functions such as memory and thinking by increasing the amount of certain naturally occurring substances in the brain and amplifying communication channels between nerve cells, which are less active in patients with mild to moderate Alzheimer's disease. Currently, the drug is used in clinical applications in oral form and patch form.
LY03013 is an innovative patch dosage form of lisdexamfetamine. According to the press release, compared with lisdexamfetamine transdermal patch (single-day patch), LY03013 has a lower frequency of use, which can improve patients' medication adherence; compared with oral formulations, the drug is absorbed by the human body through penetrating the skin, which also provides a good ease of use for patients with dysphagia and is expected to reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting.
We look forward to seeing this innovative patch therapy come to patients soon, bringing better treatment options for Alzheimer's disease patients! Lisdexamfetamine is a drug in the cholinesterase inhibitor class that is used clinically to treat mild to moderate dementia associated with Alzheimer's disease. This class of drugs improves cognitive functions such as memory and thinking by increasing the amount of certain naturally occurring substances in the brain and amplifying communication channels between nerve cells, which are less active in patients with mild to moderate Alzheimer's disease. Currently, the drug is used in clinical applications in oral form and patch form.
LY03013 is an innovative patch dosage form of lisdexamfetamine. According to the press release, compared with lisdexamfetamine transdermal patch (single-day patch), LY03013 has a lower frequency of use, which can improve patients' medication adherence; compared with oral formulations, the drug is absorbed by the human body through penetrating the skin, which also provides a good ease of use for patients with dysphagia and is expected to reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting.
We look forward to seeing this innovative patch therapy come to patients soon, bringing better treatment options for Alzheimer's disease patients!